HCHenrique Lima Couto

Henrique Lima Couto

*This is an algorithmically generated author record based on publicly available information.

Henrique Lima Couto has a total of 261 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • ASO Visual Abstract: Cavity Margins Sample Shaving Evaluation as Part of Vacuum-Assisted Breast Biopsy: A Potential Approach to Predict Breast Cancer Excision

    by Paula Clarke, Eduardo Carvalho Pessoa, Bertha Andrade Coelho, Daniel de Araújo Brito Buttros, Aleida N. Soares, Bruna Torres Silvestre da Silva, Hélio Rubens de Carvalho Nunes, Carla Priscila Kamiya Carvalho Pessoa, Amanda Cristina Braga de Oliveira, Tereza Cristina de Oliveira Ferreira, et al.

  • Open Access

    Cavity Margins Sample Shaving as Part of Extended Vacuum-Assisted Breast Biopsy: A Potential Approach to Predict Percutaneous Breast Cancer Excision

    by Paula Clarke, Eduardo Carvalho Pessoa, Bertha Andrade Coelho, Daniel de Araújo Brito Buttros, Aleida Nazareth Soares, Bruna Torres Silvestre da Silva, Hélio Rubens de Carvalho Nunes, Carla Priscila Kamiya Carvalho Pessoa, Amanda Cristina Braga de Oliveira, Tereza Cristina de Oliveira Ferreira, et al.

    Background: Excision of small breast cancers has been reported by vacuum-assisted biopsy (VAB). Nevertheless, patients are submitted to surgery, because there is no way to predict excision. The purpose of this study was to evaluate extended vacuum-assisted biopsy (EVAB) associated with cavity margins sample shaving (CMSH) to predict breast cancer excision. Methods: This is a retrospective database analysis of 120 cancers [both invasive breast cancers (IC) and ductal carcinoma in situ (DCIS)] diagnosed by EVAB-CMSH submitted to surgery with histological data from EVAB-CMSH and surgery. The CMSH was evaluated as a diagnostic test for excision compared to surgery as gold standard. Factors associated with residual tumor, gross residual tumor (GRD) (> 3 mm), and false-negative CMSH after EVAB-CMSH were evaluated. Results: A total of 120 cases were analyzed. Media age was 57 (48.5–69); image tumor size ( T ) was 11 (8.6–15) mm; pathological tumor size (pT) was 6 (4–10) mm; most cases IC+DCIS 53 (44.2%), DCIS 46 (38.3%), and IC 15 (12.5%); 45 (37.5%) were excised by EVAB-CMSH. CMSH sensitivity 70.7%, specificity 66.7%, false-negative rate 18.33%, and accuracy 69.2%. In multivariate analysis, DCIS pT ( p = 0.003, odds ratio [OR] 1.46, 95% confidence interval [CI]) was associated with residual tumor; DCIS pT ( p = 0.001, OR 1.34, 95% CI) and the CMSH T ( p = 0.001, OR 1.67, 95% CI) with GRD; surgical specimen DCIS T ( p = 0.015, OR 1.12, 95% CI) with CMSH false negative. Conclusions: Cavity margins sample shaving is a potential approach to predict small breast cancer excision and should be added to vacuum-assisted excision in prospective trials. For DCIS, EVAB-CMSH should not be standard of care.


  • Open Access

    Severe Adverse Events in Neoadjuvant Therapy of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Phase 3 Trials

    by Marcelo Antonini, André Mattar, Marcelo Madeira, Francisco Pimentel Cavalcante, Felipe Pereira Zerwes, Fabricio Palermo Brenelli, Antonio Luis Frasson, Eduardo Camargo Millen, Giuliano Tavares Tosello, Marina Diogenes Teixeira, et al.


  • Open Access

    Breast MRI biomarkers of tumor biology: integrating imaging with pathology to guide clinical care

    by Eduardo Carvalho Pessoa, Henrique Lima Couto, Carla Priscila Kamyia Carvalho Pessoa, Ana Beatriz da Silva Pina, Heloisa Maria de Luca Vespolli, Benedito de Souza Almeida Filho, Denia Reis de Paula, Eliana Aguiar Petri Nahas

  • Open Access

    Clinical Guidelines from the 2025 International Symposium on Breast Diseases of Inland São Paulo: Imaging Assessment and Management of B3 Breast Lesions

    by Eduardo Carvalho Pessoa, Fabio Bagnoli, Marcelo Madeira, Joaquim Teodoro Araujo, Giuliano Tosello, Fabricio Brenelli, Beatriz Geronymo, Daniel de Araujo Buttros, Bruna Salani Mota, Henrique Lima Couto, et al.

    Objective: To establish evidence-based clinical guidelines from the 2025 International Symposium on Breast Diseases of Inland São Paulo (SIMIP 2025), addressing four key axes of breast cancer diagnosis and management: indications for preoperative magnetic resonance imaging (MRI), vacuum-assisted excision (VAE) for B3 lesions (breast lesions of uncertain malignant potential), supplemental imaging for dense breasts, and the preferred imaging modality (contrast-enhanced mammography [CEM] or MRI) for high-risk women. Methods: Each axis was presented in evidence-based lectures, followed by debates and anonymous electronic voting by 100 specialists. Consensus was defined as ≥75% agreement. Results: Preoperative MRI was recommended for selected cases (100% in favor), including invasive lobular carcinoma, dense breasts, and occult carcinoma. VAE for B3 lesions received 98% support, except for phyllodes tumors and papillary lesions with atypia. Supplemental imaging for dense breasts was unanimously endorsed (64% preferred MRI, 36% voted for ultrasound). For high-risk women, MRI was chosen by 100%, with CEM as an alternative. Conclusion: The guidelines reinforce MRI for selected preoperative cases and high-risk screening, emphasize VAE as an effective approach for managing B3 lesions, and advocate for supplemental imaging (preferably MRI) for dense breasts, with multidisciplinary decision-making.

  • Open Access

    Breast cancer in women 40–50 and over 70 years of age: the need for screening in Brazil

    by Ivie Braga de Paula, Luciano Fernandes Chala, Linei Augusta Brolini Delle Urban, Almir Galvão Vieira Bitencourt, Tatiane Mendes Gonçalves de Oliveira, Henrique Lima Couto, Paula de Camargo Moraes, Beatriz Medicis Maranhão Miranda, Thaís Paiva Moraes, Ana Claudia Mendes Rodrigues Mussauer, et al.

    Breast cancer is the most common malignancy among women in Brazil and the leading cause of cancer-related death in the female population of the country. Despite advances in treatment and the implementation of mammography screening programs, mortality rates have continued to rise. This increase is particularly evident among women under 50 years of age and those 70 years of age or older, groups that account for a substantial proportion of diagnosed cases and registered deaths in the country. Until recently, these age groups were not included in the screening guide-lines established by the Brazilian National Ministry of Health, although consistent scientific evidence demonstrates significant benefits of early detection in these populations, including reduced mortality, a higher proportion of early-stage diagnoses, and less aggressive therapeutic interventions. This article analyzes epidemiological data, the socio-economic impacts of breast cancer, and the scientific evidence regarding mammography screening, discussing the outcomes and limitations of national programs in Brazil. On the basis of that analysis, we advocate for the revision and expansion of public breast cancer screening policies to include women 40–49 and ≤ 70 years of age, as an essential strategy to reduce mortality, improve clinical outcomes, and promote greater equity in access to diagnosis and treat-ment of breast cancer in Brazil.

  • Open Access

    Clinical characteristics and prognostic impact of HER2 low expression in breast cancer subtypes from a Brazilian real-world cohort

    by André Mattar, Marcelo Antonini, Francisco Pimentel Cavalcante, Felipe Zerwes, Eduardo Camargo Millen, Fabricio Palermo Brenelli, Antônio Luiz Frasson, Marcelo Madeira, Marina Diógenes Teixeira, Andressa Gonçalves Amorim, et al.

    Breast cancer (BC) is the most prevalent cancer among Brazilian women, yet related data remain limited. The HER2-low classification has gained significance with the advent of targeted therapies. This study aimed to assess survival outcomes of HER2-low BC compared to other subtypes in a real-world Brazilian cohort. We analyzed data from 8,485 breast cancer patients treated at Pérola Byington Hospital between 2010 and 2019. Overall survival (OS) was the primary endpoint, stratified by cancer subtype. The t-test and chi-square test evaluated variable associations, while multivariate analysis calculated odds ratios and 95% confidence intervals. Cox regression assessed survival, and Kaplan–Meier curves illustrated OS differences. The patients with HER2-low breast cancers showed significantly better overall survival than those with the triple-negative subtype (p < 0.01). However, they had significantly poorer overall survival than those with the Luminal A-like subtype (p < 0.01). The patients with triple-negative HER2-low disease had a higher risk of mortality than those with HER2-0 (p < 0.01). Finally, patients who achieved pathological complete response experienced significantly better overall survival than those who did not (p < 0.01). Our findings highlight triple negative HER2-low BC as a distinct subtype identifiable via standard immunohistochemistry, beyond just biomarker status. The study underscores the prognostic diversity among BC subtypes and emphasizes the importance of personalized treatment strategies.


  • Immunohistochemical Changes After Neoadjuvant Chemotherapy and Their Impact on Breast Cancer Survival: A Systematic Review and Meta-analysis

    by Marcelo Antonini, André Mattar, Gil Facina, Francisco Pimentel Cavalcante, Felipe Zerwes, Fabricio Palermo Brenelli, Antônio Luis Frasson, Eduardo Camargo Millen, Rodrigo Caires Campos, Letícia Xavier Félix, et al.


  • Open Access

    Vacuum-assisted excision: one-step approach to the diagnosis and percutaneous treatment of small early breast cancer (the VAE-BREAST 01 study protocol)

    by Henrique Lima Couto, Bertha Andrade Coelho, Bernardo Ferreira de Paula Ricardo, Paola Hartung Toppa, Aleida Nazareth Soares, Bruna Torres Silvestre da Silva, Douglas de Miranda Pires, Tereza Cristina de Oliveira Ferreira, Paula Clarke, Shirley das Graças Ferreira, et al.

    Introduction: Vacuum-assisted excision (VAE) of breast lesions is a technique used for diagnostic and therapeutic purposes and is performed on an outpatient basis, with local anesthesia and image guidance. Currently, VAE is used in the management of benign lesions and lesions of uncertain malignant potential (B3 lesions). More recently, there has been interest in VAE for the percutaneous treatment of small breast cancers, the aim of which was to reduce morbidity and aggressive surgical treatment. Due to how conventional VAE is performed, histopathological assessment of the resection margins is not possible. Obtaining free margins after a breast cancer resection is a primary objective in the surgical treatment of this disease. If VAE could ensure free margins and the absence of residual tumor in the surgical excision, it would represent a safe method for a minimally invasive treatment, providing an effective percutaneous treatment of small early breast cancers. Methods: The prospective VAE-BREAST 01 study explores the role of VAE associated with cavity margin sample shaving (CMSH) as a one-step approach in the diagnosis and complete excision of small breast tumors, ensuring the absence of residual disease in surgical pathology. Women with lesions smaller than 1.5 cm, ACR BI-RADS™ (American College of Radiology Breast Imaging Reporting and Data System) category 4 or 5, and identified by screening or clinical alteration are included. Multifocal, multicentric breast cancers and breast cancers associated with diffuse and extensive calcifications are excluded. The sensitivity, specificity, accuracy, positive predictive value, negative predictive value, and the false-negative and false-positive rates of VAE+CMSH for the complete excision of breast cancers will be calculated. The collected data also will include patients’ demographics, image characteristics of the lesions, information regarding the VAE+CMSH and surgical procedure, biopsy and surgical pathology, and data on side effects, patient acceptance, cosmetic results, and patients’ experiences during VAE. Ethics and dissemination: Ethics approval was obtained from the Brazilian National Research Ethics Commission (CONEP). Participants will provide written informed consent, and researchers will follow institutional guidelines for data collection and management. Clinical Trial Registration: https://ensaiosclinicos.gov.br/ , identifier U1111-1301-4235